What is Sanifit?
Founded in 2007 as a spin-off from the University of the Balearic Islands, Sanifit operates at the intersection of biotechnology and specialized medicine. The company is dedicated to the development of innovative treatments for calcification disorders, a therapeutic area characterized by significant unmet medical needs. By focusing on the underlying mechanisms of calcification, Sanifit has established a unique market position, distinguishing itself from traditional pharmaceutical players through its targeted, science-led methodology. The firm's growth trajectory, marked by successive rounds of institutional financing, reflects its evolution from an academic spin-off into a mature clinical-stage biopharmaceutical entity.
How much funding has Sanifit raised?
Sanifit has raised a total of $151.4M across 3 funding rounds:
Series C
$29.5M
Series B
$41M
Series D
$80.9M
Series C (2015): $29.5M with participation from Columbus Venture Partners SGEIC, Caixa Capital Risc, and Alta Life Sciences
Series B (2015): $41M led by Gilde Healthcare, Forbion Capital Partners, Ysios Capital, Lundbeck and Baxter Healthcare, Edmond de Rothschild Investment Partners, and La Caixa
Series D (2019): $80.9M supported by Columbus Venture Partners SGEIC, Caixa Capital Risc, and Alta Life Sciences
Key Investors in Sanifit
Columbus Venture Partners SGEIC
Columbus Venture Partners is a venture capital firm focused on advancing biotechnology that transforms lives and generates solid returns. They invest in therapeutic and industrial products through life science funds, aiming to lead therapeutic innovation in the Spanish biotech sector.
Caixa Capital Risc
CriteriaCaixa is a venture capital firm focused on investing in innovative startups at early stages, particularly in technology, biotechnology, and the industrial sector. They manage investments through specialized funds including Criteria Bio Ventures.
Alta Life Sciences
Alta Life Sciences is a venture capital firm specializing in the life sciences sector, providing strategic capital to companies developing innovative healthcare solutions and therapeutic breakthroughs.
What's next for Sanifit?
Looking ahead, Sanifit is poised to utilize its recent capital infusion to bolster its clinical trial infrastructure and expand its research capabilities. The strategic focus remains on the successful execution of late-stage development programs, which are essential for achieving regulatory approval and eventual commercialization. As the company scales, it will likely prioritize the optimization of its therapeutic pipeline and the strengthening of its intellectual property portfolio. The continued support from specialized life science investors suggests a clear path toward achieving long-term value creation and addressing the global burden of calcification-related pathologies.
See full Sanifit company page
